Aptose Biosciences

151 articles with Aptose Biosciences

• Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium

  3/28/2023

  Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format.

• Aptose Reports Results for the Fourth Quarter and Full Year 2022

  3/23/2023

  Aptose Biosciences Inc. announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

• Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

  3/10/2023

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to Silicon Valley Bank and questions raised by interested parties.

• Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

  3/9/2023

  Aptose Biosciences Inc. will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update.

• Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

  3/2/2023

  Aptose Biosciences Inc. today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.

• Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

  1/30/2023

  Aptose Biosciences Inc. today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib.

• Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference

  12/28/2022

  Aptose Biosciences Inc. announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA.

• Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

  12/11/2022

  Aptose Biosciences Inc. provided a clinical update of its lead oral myeloid kinome inhibitor, tuspetinib, as responses continue to emerge from a Phase 1/2 trial, and from its oral, dual lymphoid and myeloid kinase inhibitor, luxeptinib in an ongoing Phase 1a/b trial.

• Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

  12/7/2022

  Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that the company’s management team will provide a corporate update on Sunday, December 11, 2022, at 10:00 AM EST / 9:00 CST, in conjunction with poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, LA.

• Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

  11/14/2022

  Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML).

• Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting

  11/3/2022

  Aptose Biosciences Inc. announced that clinical data for tuspetinib, a myeloid kinome inhibitor, and luxeptinib, a dual lymphoid and myeloid inhibitor, have been accepted for poster presentations at the 64th American Society of Hematology Annual Meeting and Exposition, being held Saturday, December 10 – Monday, December 13, 2022 in New Orleans, LA and virtually.

• Aptose Reports Results for the Third Quarter 2022

  11/1/2022

  Aptose Biosciences Inc. announced financial results for the three and nine-month periods ended September 30, 2022 and provided a corporate update.

• Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022

  10/18/2022

  Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended September 30, 2022, on Tuesday, November 1, 2022 after the close of the market, and provide a corporate update.

• Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

  9/14/2022

  Aptose Biosciences Inc. today announced that the Aptose will be participating in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022.

• Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.New director brings big pharma oncology experience and biotech leadership

  9/13/2022

  Aptose Biosciences Inc. today announced the appointment of Bernd R. Seizinger, M.D., Ph.D., to the Board of Directors, effective immediately.

• Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

  9/12/2022

  Aptose Biosciences Inc. announced the G3 formulation of luxeptinib, designed for rapid and efficient absorption, demonstrates approximately an 18-fold improvement in oral bioavailability relative to the original G1 formulation, and that Aptose plans to move forward with the development of the G3 formulation of luxeptinib to determine if it can achieve desired exposures and deliver clinical responses while continuing to demonstrate a favorable safety profile.

• Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  8/30/2022

  Aptose Biosciences Inc. today announced that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City.

• Aptose Reports Results for the Second Quarter 2022

  8/2/2022

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months ended June 30, 2022 and provided a corporate update.

• Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

  7/27/2022

  Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference.

• Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

  7/19/2022

  Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended June 30, 2022, on Tuesday, August 2, 2022 after the close of the market, and provide a corporate update.